Initiator Pharma A/S (STO:INIT)
Sweden · Delayed Price · Currency is SEK 2.110
-0.050 (-2.31%)
Sep 23, 2026, 10:00 AM CET
Initiator Pharma Balance Sheet
Financials in millions DKK. Fiscal year is January - December.
Millions DKK. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 17.07 | 26.25 | 13.37 | 24.34 | 39.11 | 34.35 |
Cash & Short-Term Investments | 17.07 | 26.25 | 13.37 | 24.34 | 39.11 | 34.35 |
Cash Growth | 263.19% | 96.28% | -45.06% | -37.78% | 13.88% | 154.34% |
Other Receivables | 3.81 | 4.12 | 2.45 | 5.43 | 7.21 | 4.13 |
Receivables | 3.81 | 4.12 | 2.45 | 5.43 | 7.21 | 4.13 |
Prepaid Expenses | - | 3.38 | - | - | 2.01 | 15.23 |
Total Current Assets | 20.88 | 33.74 | 15.82 | 29.77 | 48.33 | 53.7 |
Property, Plant & Equipment | - | 0.02 | 0.02 | - | - | - |
Other Long-Term Assets | 0.02 | - | - | 0.02 | 0.02 | - |
Total Assets | 20.9 | 33.76 | 15.84 | 29.79 | 48.35 | 53.7 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 1 | 0.86 | 0.37 | 0.41 | 0.8 | 4.8 |
Accrued Expenses | 1.41 | 1.01 | 0.49 | 2.53 | - | - |
Other Current Liabilities | 0.31 | 0.19 | 0.2 | 0.25 | 0.94 | 0.62 |
Total Current Liabilities | 2.72 | 2.06 | 1.05 | 3.19 | 1.75 | 5.42 |
Long-Term Debt | 9.67 | 2.15 | - | 15.44 | 12.58 | 13.29 |
Total Liabilities | 12.38 | 4.21 | 1.05 | 18.62 | 14.32 | 18.71 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 7.19 | 7.19 | 5.9 | 5.51 | 5.5 | 4.6 |
Retained Earnings | 1.32 | 22.36 | 8.89 | 5.65 | 28.53 | 30.4 |
Shareholders' Equity | 8.51 | 29.55 | 14.78 | 11.16 | 34.02 | 34.99 |
Total Liabilities & Equity | 20.9 | 33.76 | 15.84 | 29.79 | 48.35 | 53.7 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 9.67 | 2.15 | - | 15.44 | 12.58 | 13.29 |
Net Cash (Debt) | 7.4 | 24.1 | 13.37 | 8.9 | 26.54 | 21.06 |
Net Cash Growth | 194.78% | 80.21% | 50.25% | -66.46% | 26.02% | 55.92% |
Net Cash Per Share | 0.11 | 0.39 | 0.24 | 0.17 | 0.55 | 0.60 |
Filing Date Shares Outstanding | 68.45 | 68.45 | 56.16 | 52.47 | 52.36 | 43.77 |
Total Common Shares Outstanding | 68.45 | 68.45 | 56.16 | 52.47 | 52.36 | 43.77 |
Working Capital | 18.16 | 31.68 | 14.77 | 26.58 | 46.58 | 48.28 |
Book Value Per Share | 0.12 | 0.43 | 0.26 | 0.21 | 0.65 | 0.80 |
Tangible Book Value | 8.51 | 29.55 | 14.78 | 11.16 | 34.02 | 34.99 |
Tangible Book Value Per Share | 0.12 | 0.43 | 0.26 | 0.21 | 0.65 | 0.80 |